Hologic, Inc. (HOLX) EPS Estimated At $0.53 on May, 9

April 17, 2018 - By Robert Reynolds

Hologic, Inc. (NASDAQ:HOLX) Corporate Logo
Big Money Sentiment decreased to 0.74 in 2017 Q4. It has change of 0.14, from 2017Q3’s 0.88. The ratio is negative due to Hologic, Inc. positioning: 57 sold and 165 reduced. 70 funds acquired positions and 94 increased positions. Investors holded 265.54 million in 2017Q3 but now own 264.36 million shares or 0.45% less.
Shell Asset Management Communication owns 18,357 shs or 0.02% of their US capital. State Board Of Administration Of Florida Retirement System stated it has 413,830 shs or 0.05% of all its holdings. Advantus Capital Management invested in 0.03% or 28,320 shs. At National Bank & Trust invested 0.29% of its capital in Hologic, Inc. (NASDAQ:HOLX). The New York-based Jane Street Group Incorporated Ltd has invested 0% in Hologic, Inc. (NASDAQ:HOLX). Central Bancorporation, a Kentucky-based fund reported 17,132 shs. 812,916 were reported by Davis R M Inc. Massachusetts-based Panagora Asset Mgmt has invested 0% in Hologic, Inc. (NASDAQ:HOLX). Advisory Svcs Network Ltd Company holds 0.1% of its capital in Hologic, Inc. (NASDAQ:HOLX) for 26,253 shs. Whittier Trust holds 0% or 231 shs in its capital. 138,173 are held by Teachers Retirement Systems Of The State Of Kentucky. Gofen & Glossberg Il accumulated 5,645 shs or 0.01% of the stock. Hanson And Doremus Inv Mgmt holds 400 shs or 0.01% of its capital. Natl Pension Serv reported 0% stake. 16,390 are owned by Ls Inv Ltd Llc.

Hologic, Inc. registered $682,999 net activity with 3 insider buys and 1 sale since February 13, 2018. 7,000 Hologic, Inc. (NASDAQ:HOLX) shs with value of $271,250 were sold by Bebo Allison P. Nawana Namal also bought $250,023 worth of Hologic, Inc. (NASDAQ:HOLX) on Tuesday, February 13. Wendell Amy McBride bought $199,826 worth of Hologic, Inc. (NASDAQ:HOLX) or 5,200 shs on Wednesday, March 14.

Investors expect Hologic, Inc. (NASDAQ:HOLX)’s quarterly earnings on May, 9., according to RTT. The EPS diference is $0.03 or 6.00 % up from last years number. Previous year: $0.5; Analysts forcast: $0.53. If $0.53 is reported, HOLX’s profit will reach $146.56 million for 17.78 P/E. Analysts at Wall Street see Hologic, Inc.’s -3.64 % negative EPS growth compared to $0.55 EPS for last quarter. On during the last trading session the stock increased $0.67 or 1.81%, reaching $37.69.Hologic, Inc. has volume of 1.15 million shares. Since April 17, 2017 HOLX has declined 11.91% and is downtrending. HOLX underperformed the S&P500 by 23.46%.

Hologic, Inc. (NASDAQ:HOLX) Ratings Coverage

In total 12 analysts cover Hologic (NASDAQ:HOLX). “Buy” rating has 9, “Sell” are 0, while 3 are “Hold”. 75% are bullish. 17 are the (NASDAQ:HOLX)’s analyst reports since December 11, 2017 according to StockzIntelligence Inc. On Friday, February 9 the firm earned “Buy” rating by Canaccord Genuity. The company rating was maintained by Needham on Tuesday, January 9. On Monday, December 11 Cowen & Co upgraded Hologic, Inc. (NASDAQ:HOLX) to “Outperform” rating. On Wednesday, January 3 the stock has “Buy” rating by Canaccord Genuity. In Friday, February 9 report Needham maintained it with “Buy” rating and $50.0 target. On Thursday, February 8 the firm has “Buy” rating given by Piper Jaffray. On Friday, February 9 Stifel Nicolaus downgraded Hologic, Inc. (NASDAQ:HOLX) to “Hold” rating. On Wednesday, December 20 the stock of Hologic, Inc. (NASDAQ:HOLX) has “Buy” rating given by Cowen & Co. On Friday, February 9 the stock of Hologic, Inc. (NASDAQ:HOLX) earned “Hold” rating by RBC Capital Markets. On Thursday, January 4 the rating was upgraded by Bank of America to “Buy”.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally.The company has $10.42 billion market cap. It operates through four divisions: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health.The P/E ratio is 9.98. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test.

Hologic, Inc. (NASDAQ:HOLX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.